stockrow
Saturday 7 November 2026
Export OBX’s income statement to Excel — free account
Obsidian Therapeutics, Inc
14.02
4.42
+46.04%
Follow OBX
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
5.31 | 10.75 |
Net Debt/EBITDA |
0.77 | 1.88 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.90 | 0.90 |
Capex/Depreciation |
(0.05) | (0.51) |
| 45.68% | 0.00% | |
| (73.90%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(147.81%) | (51.92%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(6.49) | (5.90) |
Cash per Share |
5.78 | 13.10 |
Shareholders Equity per Share |
(19.09) | (13.58) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(19.09) | (13.58) |
Free Cash Flow |
(90.47) | (75.78) |
Working Capital |
66.15 | 156.76 |
Capital Expenditures |
(0.07) | (0.78) |
Net Current Asset Value |
(273.10) | (185.30) |
| Other line items | ||
Quick Ratio |
5.24 | 10.46 |
Depreciation/Fixed assets |
0.78 | 0.46 |
Cash ROIC |
48.76% | 1,230.01% |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(6.49) | (5.84) |
Capex per Share |
(0.01) | (0.06) |
Average Payables |
0.92 | — |
Average Assets |
136.15 | — |
Average Common Equity |
(220.23) | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026